Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
FC(PO)+R
- Cancer Type
- Hematologic, Lymphoma - Non-Hodgkin's Low Grade
- Intent
-
Palliative
- Regimen Category
-
Evidence-informed
- Funding Program
-
ODB - General Benefit cyclophosphamide - oral tablets New Drug Funding Program Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
- Drugs Used
- riTUXimab , fludarabine , cyclophosphamide , riTUXimab (subcut)
- QBP Type
-
Unfunded This drug is not currently publicly funded for this regimen and intent
Regimen Monograph
Aug 2020
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 27, 2026
